Table I.
Patient characteristics.
| Variables | No. of patients |
|---|---|
| Age, years [median (range)] | 56 (26–78) |
| Histological type | |
| Serous | 101 |
| Endometrioid | 18 |
| Clear cell | 26 |
| Mucinous | 11 |
| First-line regimen | |
| TC | 135 |
| DC | 10 |
| CPT-P | 6 |
| CAP | 5 |
| No. of first-line chemotherapy cycles [median (range)] | 6 (1–13) |
| Debulking surgery | |
| Complete | 31 |
| Optimal | 39 |
| Suboptimal | 86 |
| Response to first-line chemotherapy | |
| Complete response | 107 |
| Partial response | 26 |
| Stable disease | 4 |
| Progressive disease | 19 |
| CR according to histological type [CR/non-CR (%)] | |
| Serous | 73/101 (72.3) |
| Endometrioid | 12/18 (66.7) |
| Clear cell | 16/26 (61.5) |
| Mucinous | 6/11 (54.5) |
| Recurrence sites after CR | |
| Intraabdominal | 45 |
| Intrapelvic | 44 |
| Distant | 18 |
| Second-line regimen | |
| Platinum-based | 70 |
| Non-platinum-based | 37 |
TC, paclitaxel/carboplatin; DC, docetaxel/carboplatin; CPT-P, irinotecan (CPT-11)/cisplatin; CAP, cyclophosphamide/adriamycin/cisplatin; CR, complete response.